Liquidia (NASDAQ:LQDA) CAO Sells 5,892 Shares of Company Stock

Liquidia Corporation (NASDAQ:LQDA) CAO Dana Boyle sold 5,892 shares of the firm’s stock in a transaction on Monday, October 12th. The stock was sold at an average price of $28.48, for a total value of $167,804.16. Following the completion of the transaction, the chief accounting officer owned 165,609 shares in the company, valued at $4,716,544.32. The trade was a 3.44% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Dana Boyle also recently made the following trade(s):

• On Monday, July 27th, Dana Boyle sold 1,600 shares of Liquidia stock. The shares were sold at an average price of $87.53, for a total value of $140,048.00.

Liquidia Price Performance

LQDA traded down $0.86 on Tuesday, hitting $26.81. 3,092,611 shares of the stock were exchanged, compared to its average volume of 5,078,983. Liquidia Corporation has a 12 month low of $21.94 and a 12 month high of $93.61. The business has a 50-day moving average of $63.40 and a two-hundred day moving average of $61.76. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.31 and a quick ratio of 2.12. The firm has a market capitalization of $2.40 billion, a price-to-earnings ratio of 19.57 and a beta of 0.61.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Wednesday, August 12th. The company reported $0.74 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). Liquidia had a return on equity of 149.65% and a net margin of 30.74%. The firm had revenue of $171.68 million for the quarter, compared to analyst estimates of $168.48 million. During the same quarter in the previous year, the company earned ($0.49) earnings per share. The company’s quarterly revenue was up 1842.1% on a year-over-year basis. Sell-side analysts forecast that Liquidia Corporation will post 2.05 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. WINTON GROUP Ltd acquired a new position in Liquidia during the second quarter worth about $335,000. Arizona State Retirement System lifted its holdings in shares of Liquidia by 5.4% in the second quarter. Arizona State Retirement System now owns 17,627 shares of the company’s stock worth $1,405,000 after acquiring an additional 900 shares during the last quarter. Nykredit A S bought a new position in shares of Liquidia in the second quarter worth about $177,000. Corient Private Wealth LP acquired a new stake in shares of Liquidia in the 2nd quarter valued at approximately $758,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of Liquidia in the 2nd quarter valued at approximately $1,236,000. Institutional investors own 64.54% of the company’s stock.

Key Stories Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia reached a global settlement with United Therapeutics that resolves all six pending lawsuits and allows uninterrupted commercialization of YUTREPIA for pulmonary arterial hypertension (PAH). Eliminating years of patent, antitrust and trade-secret litigation reduces regulatory and commercial uncertainty. Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics
• Positive Sentiment: Preliminary third-quarter YUTREPIA net product sales were $222.7 million, while cash and cash equivalents stood at $396.1 million at September 30. Management said it expects to fund the settlement and planned clinical programs from cash and ongoing sales without additional financing. The company also plans to continue developing YUTREPIA and L606.
• Neutral Sentiment: Multiple executives and insiders—including the CEO, CFO, CAO and general counsel—sold shares at $28.48 under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. The sales reduced individual holdings but were not discretionary open-market transactions, making them a limited standalone signal of management confidence. Liquidia insider sale filing
• Negative Sentiment: Liquidia will pay United Therapeutics a net $380.7 million: $175 million within 30 business days, $145.4 million in installments during 2027 and $60.3 million related to the antitrust litigation. The outflows could materially reduce its cash cushion and constrain investment, even though management expects to rebuild cash through YUTREPIA sales.
• Negative Sentiment: The company agreed not to appeal a patent-infringement ruling and is removing the PH-ILD indication from YUTREPIA’s label, limiting the product’s addressable market. Liquidia also ended promotion of Treprostinil Injection, eliminating associated commercial revenue opportunities.
• Negative Sentiment: Recent insider activity remains heavily tilted toward selling—106 sales versus one purchase over six months—and a report highlighted a chairman’s share sale. Separately, a law firm announced an investor investigation related to disclosure of YUTREPIA litigation risks, adding potential reputational and legal uncertainty. Liquidia Negatively Rated Stock Pick of the Week

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on LQDA. Weiss Ratings upgraded shares of Liquidia from a “sell (d-)” rating to a “hold (c)” rating in a research report on Tuesday, September 22nd. Stephens set a $130.00 price objective on shares of Liquidia in a research report on Friday, July 24th. Zacks Research downgraded shares of Liquidia from a “hold” rating to a “strong sell” rating in a research report on Tuesday, September 22nd. Wells Fargo & Company restated an “equal weight” rating and set a $30.00 target price (down from $108.00) on shares of Liquidia in a research note on Friday, October 2nd. Finally, Bank of America upped their target price on Liquidia from $79.00 to $92.00 and gave the stock a “neutral” rating in a research note on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $83.69.

About Liquidia

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).